TNF-α-mediated anxiety in a mouse model of multiple sclerosis

Experimental Neurology

Volumn 237, Issue 2, 2012, Pages 296-303

  Haji, Nabila ^a,b   Mandolesi, Georgia ^a   Gentile, Antonietta ^a   Sacchetti, Lucia ^c   Fresegna, Diego ^a   Rossi, Silvia ^a,d   Musella, Alessandra ^a   Sepman, Helena ^a   Motta, Caterina ^a,d   Studer, Valeria ^a,d   De Chiara, Valentina ^a,d   Bernardi, Giorgio ^a,d   Strata, Piergiorgio ^b   Centonze, Diego ^a,d  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anxiety like behavior; EPSC; Experimental autoimmune encephalomyelitis; Inflammation; Striatum; TNF

Indexed keywords

ETANERCEPT; GLUTAMIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CELL ACTIVATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE RELEASE; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; GLUTAMATERGIC TRANSMISSION; MICROGLIA; MOTOR DYSFUNCTION; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

ANIMALS; ANXIETY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MULTIPLE SCLEROSIS; PATCH-CLAMP TECHNIQUES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864821484     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.07.010     Document Type: Article

References (63)

1. Aktas O., Zipp F. Regulation of self-reactive T cells by human immunoglobulins-implications for multiple sclerosis therapy. Curr. Pharm. Des. 2003, 9:245-256.
2. Bakshi V.P., Smith-Roe S., Newman S.M., Grigoriadis D.E., Kalin N.H. Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J. Neurosci. 2002, 22:2926-2935.
3. Balkowiec-Iskra E., Vermehren-Schmaedick A., Balkowiec A. Tumor necrosis factor-alpha increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activity-dependent manner. Neuroscience 2011, 180:322-333.
4. Baune B.T., Dannlowski U., Domschke K., Janssen D.G., Jordan M.A., Ohrmann P., Bauer J., Biros E., Arolt V., Kugel H., Baxter A.G., Suslow T. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol. Psychiatry 2010, 67:543-549.
5. Bercik P., Verdu E.F., Foster J.A., Macri J., Potter M., Huang X., Malinowski P., Jackson W., Blennerhassett P., Neufeld K.A., Lu J., Khan W.I., Corthesy-Theulaz I., Cherbut C., Bergonzelli G.E., Collins S.M. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology 2010, 139:2102-2112.
6. Bermel R.A., Innus M.D., Tjoa C.W., Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport 2003, 14:335-339.
7. Bluthe R.M., Dantzer R., Kelley K.W. Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor alpha in mice. Eur. J. Pharmacol. 1991, 209:281-283.
8. Capuron L., Hauser P., Hinze-Selch D., Miller A.H., Neveu P.J. Treatment of cytokine-induced depression. Brain Behav. Immun. 2002, 16:575-580.
9. Centonze D., Rossi S., Prosperetti C., Gasperi V., De Chiara V., Bari M., Tscherter A., Febbraro F., Bernardi G., Maccarrone M. Endocannabinoids limit metabotropic glutamate 5 receptor-mediated synaptic inhibition of striatal principal neurons. Mol. Cell. Neurosci. 2007, 35:302-310.
10. Centonze D., Muzio L., Rossi S., Cavasinni F., De Chiara V., Bergami A., Musella A., D'Amelio M., Cavallucci V., Martorana A., Bergamaschi A., Cencioni M.T., Diamantini A., Butti E., Comi G., Bernardi G., Cecconi F., Battistini L., Furlan R., Martino G. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 2009, 29:3442-3452.
11. Clark I.A., Alleva L.M., Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol. Ther. 2010, 128:519-548.
12. Clem R.L., Huganir R.L. Calcium-permeable AMPA receptor dynamics mediate fear memory erasure. Science 2010, 330:1108-1112.
13. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
14. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
15. Favilla C., Abel T., Kelly M.P. Chronic Galphas signaling in the striatum increases anxiety-related behaviors independent of developmental effects. J. Neurosci. 2008, 28:13952-13956.
16. Feinstein A. Neuropsychiatric syndromes associated with multiple sclerosis. J. Neurol. 2007, 254:II73-II76.
17. Fiore M., Probert L., Kollias G., Akassoglou K., Alleva E., Aloe L. Neurobehavioral alterations in developing transgenic mice expressing TNF-alpha in the brain. Brain Behav. Immun. 1996, 10:126-138.
18. Fiore M., Alleva E., Probert L., Kollias G., Angelucci F., Aloe L. Exploratory and displacement behavior in transgenic mice expressing high levels of brain TNF-alpha. Physiol. Behav. 1998, 63:571-576.
19. Fromont A., De Seze J., Fleury M.C., Maillefert J.F., Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57.
20. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
21. Herz J., Zipp F., Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp. Neurol. 2010, 225:9-17.
22. Hu H., Real E., Takamiya K., Kang M.G., Ledoux J., Huganir R.L., Malinow R. Emotion enhances learning via norepinephrine regulation of AMPA-receptor trafficking. Cell 2007, 131:160-173.
23. Imitola J., Chitnis T., Khoury S.J. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 2005, 106:163-177.
24. Kahl K.G., Kruse N., Faller H., Weiss H., Rieckmann P. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002, 27:671-681.
25. Kassiotis G., Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 2001, 193:427-434.
26. Kim K.S., Lee K.W., Baek I.S., Lim C.M., Krishnan V., Lee J.K., Nestler E.J., Han P.L. Adenylyl cyclase-5 activity in the nucleus accumbens regulates anxiety-related behavior. Neurochem. 2008, 107:105-115.
27. Krishnan R., Cella D., Leonardi C., Papp K., Gottlieb A.B., Dunn M., Chiou C.F., Patel V., Jahreis A. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br. J. Dermatol. 2007, 157:1275-1277.
28. Lee H.K., Takamiya K., Han J.S., Man H., Kim C.H., Rumbaugh G., Yu S., Ding L., He C., Petralia R.S., Wenthold R.J., Gallagher M., Huganir R.L. Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell 2003, 112:631-643.
29. Lu W., Roche K.W. Posttranslational regulation of AMPA receptor trafficking and function. Curr. Opin. Neurobiol. 2011, (2011 Oct 14). 10.1016/j.conb.2011.09.008.
30. Lynch M.A. The multifaceted profile of activated microglia. Mol. Neurobiol. 2009, 40(2):139-156.
31. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 1995, 34:301-309.
32. Maimone D., Gregory S., Arnason B.G., Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 1991, 32:67-74.
33. Mandolesi G., Grasselli G., Musella A., Gentile A., Musumeci G., Sepman H., Haji N., Fresegna D., Bernardi G., Centonze D. GABAergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis. Neurobiol. Dis. 2012, 46:414-424.
34. Mathew S.J., Ho S. Etiology and neurobiology of social anxiety disorder. J. Clin. Psychiatry 2006, 67:9-13.
35. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Bienfait K., Dicke A., Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:474-479.
36. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
37. Murphy A.C., Lalor S.J., Lynch M.A., Mills K.H. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 2010, 24:641-651.
38. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
39. Palin K., Bluthe R.M., McCusker R.H., Levade T., Moos F., Dantzer R., Kelley K.W. The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFalpha-induced sickness behavior. Psychopharmacology 2009, 201:549-556.
40. Patanella A.K., Zinno M., Quaranta D., Nociti V., Frisullo G., Gainotti G., Tonali P.A., Batocchi A.P., Marra C. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J. Neurosci. Res. 2010, 88:1106-1112.
41. Peruga I., Hartwig S., Thone J., Hovemann B., Gold R., Juckel G., Linker R.A. Inflammation modulates anxiety in an animal model of multiple sclerosis. Behav. Brain Res. 2011, 220:20-29.
42. Pickering M., Cumiskey D., O'Connor J.J. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp. Physiol. 2005, 90:663-670.
43. Pollak Y., Orion E., Goshen I., Ovadia H., Yirmiya R. Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of 'depression due to multiple sclerosis'. Brain Behav. Immun. 2002, 16:533-543.
44. Pollak Y., Ovadia H., Orion E., Weidenfeld J., Yirmiya R. The EAE-associated behavioral syndrome: I. Temporal correlation with inflammatory mediators. J. Neuroimmunol. 2003, 137(1-2):94-99.
45. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
46. Reiman E.M., Fusselman M.J., Fox P.T., Raichle M.E. Neuroanatomical correlates of anticipatory anxiety. Science 1989, 243:1071-1074.
47. Rietberg M.B., van Wegen E.E., Uitdehaag B.M., Kwakkel G. The association between perceived fatigue and actual level of physical activity in multiple sclerosis 2011, Published online before print May 17, 2011. 10.1177/1352458511407102.
48. Rodrigues D.H., Vilela Mde C., Lacerda-Queiroz N., Miranda A.S., Sousa L.F., Reis H.J., Teixeira A.L. Behavioral investigation of mice with experimental autoimmune encephalomyelitis. Arq. Neuropsiquiatr. 2011, 69(6):938-942.
49. Rossi S., Muzio L., De Chiara V., Grasselli G., Musella A., Musumeci G., Mandolesi G., De Ceglia R., Maida S., Biffi E., Pedrocchi A., Menegon A., Bernardi G., Furlan R., Martino G., Centonze D. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav. Immun. 2010, 25:947-956.
50. Shijie J., Takeuchi H., Yawata I., Harada Y., Sonobe Y., Doi Y., Liang J., Hua L., Yasuoka S., Zhou Y., Noda M., Kawanokuchi J., Mizuno T., Suzumura A. Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J. Exp. Med. 2009, 217:87-92.
51. Soczynska J.K., Kennedy S.H., Goldstein B.I., Lachowski A., Woldeyohannes H.O., McIntyre R.S. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?. Neurotoxicology 2009, 30:497-521.
52. Steiner H., Van Waes V., Marinelli M. Fluoxetine potentiates methylphenidate-induced gene regulation in addiction-related brain regions: concerns for use of cognitive enhancers?. Biol. Psychiatry 2010, 67:592-594.
53. Stellwagen D., Beattie E.C., Seo J.Y., Malenka R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J. Neurosci. 2005, 25(12):3219-3228.
54. Suh Y., Motl R.W., Mohr D.C. Physical activity, disability, and mood in the early stage of multiple sclerosis. Disabil. Health J. 2010, 3:93-98.
55. Takeuchi H., Jin S., Wang J., Zhang G., Kawanokuchi J., Kuno R., Sonobe Y., Mizuno T., Suzumura A. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 2006, 281(30):21362-21368.
56. Tao G., Datta S., He R., Nelson F., Wolinsky J.S., Narayana P.A. Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. J. Neurol. Sci. 2009, 282(1-2):39-46.
57. Taraborrelli C., Palchykova S., Tobler I., Gast H., Birchler T., Fontana A. TNFR1 is essential for CD40, but not for lipopolysaccharide-induced sickness behavior and clock gene dysregulation. Brain Behav. Immun. 2011, 25(3):434-442.
58. Taoufik E., Tseveleki V., Chu S.Y., Tselios T., Karin M., Lassmann H., Szymkowski D.E., Taraborrelli C., Palchykova S., Tobler I., Gast H., Birchler T., Fontana A. TNFR1 is essential for CD40, but not for lipopolysaccharide-induced sickness behavior and clock gene dysregulation. Brain Behav. Immun. 2011, 25:434-442.
59. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
60. Yamada K., Iida R., Miyamoto Y., Saito K., Sekikawa K., Seishima M., Nabeshima T. Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-alpha gene: implications for emotional behavior. J. Neuroimmunol. 2000, 111:131-138.
61. Yoo H.K., Kim M.J., Kim S.J., Sung Y.H., Sim M.E., Lee Y.S., Song S.Y., Kee B.S., Lyoo I.K. Putaminal gray matter volume decrease in panic disorder: an optimized voxel-based morphometry study. Eur. J. Neurosci. 2005, 22:2089-2094.
62. Zhang H.T., Huang Y., Masood A., Stolinski L.R., Li Y., Zhang L., Dlaboga D., Jin S.L., Conti M., O'Donnell J.M. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 2008, 33:1611-1623.
63. Zorrilla E.P., Luborsky L., McKay J.R., Rosenthal R., Houldin A., Tax A., McCorkle R., Seligman D.A., Schmidt K. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 2001, 15:199-226.